Melanoma in HIV

  • Research type

    Research Study

  • Full title

    Melanoma in HIV infection: Presence of concurrent cutaneous viruses and assessment of immunogenotype

  • IRAS ID

    192031

  • Contact name

    Christopher Bunker

  • Contact email

    cbbunker@me.com

  • Sponsor organisation

    Chelsea & Westminster Hospital NHS Foundation Trust & West Middlesex University Hospital

  • Duration of Study in the UK

    2 years, 0 months, 5 days

  • Research summary

    Introduction:
    Our study aims to explore the role viruses might play in melanoma (cancer of the pigment producing cells in the skin) in the setting of a lowered immune system (immunosuppressed) secondary to human immunodeficiency virus (HIV). We are going to compare samples of melanoma from patients with and without HIV. We are also going to compare benign (non-cancerous) moles between the same groups. We are looking for the presence of viruses in the skin, looking at the response of the patient's immune system to the skin cancer (immunophenotype), and certain hereditary characteristics of the the patient's immune system (immunogenotype).

    Hypothesis:
    Melanoma arising in the setting of HIV demonstrates differences in types of concomitant viruses found in the skin, along with varied immunophenotypic and immunogenotypic characteristics compared with melanoma arising in the absence of HIV.

    Background:
    Individuals who are immunosuppressed have been shown to have higher rates of melanoma than the general population. We also know that certain viruses play a role in the development of other types of cancer in immunosuppressed people.

    Methods:
    Our study will involve analyzing tissue samples taken as part of standard, routine care for adult patients with suspected skin cancers. If possible, participants will be asked to provide a single blood sample for HLA analysis (immunogenotype). No further participation from patients is required.

    Aims:
    We hope that increased knowledge of factors contributing to development of melanoma will lead to potential innovations in prevention, monitoring and treatment.

  • REC name

    London - Camden & Kings Cross Research Ethics Committee

  • REC reference

    16/LO/0054

  • Date of REC Opinion

    2 Feb 2016

  • REC opinion

    Favourable Opinion